Anar Isman, AgelessRx, and rapamycin
Anar Isman is linked to rapamycin with high confidence; stored evidence mentions AgelessRx, which paired prescription-therapy access with rapamycin-trial participation.
Anar Isman and rapamycin: the platform records a link at 0.99 confidence. The stored evidence mentions AgelessRx, which paired access to prescription therapies with rapamycin-trial participation.
Rapamycin (sirolimus) is an FDA-approved immune-modulating and growth-inhibitory drug. In longevity medicine it is used off-label: low intermittent doses in healthy adults to maintain healthspan. The evidence base includes a 48-week randomized placebo-controlled trial in healthy adults and survey-based real-world cohorts. Safety was acceptable; some healthspan measures showed improvement. Bioavailability depends on formulation, blood levels vary between individuals, and dosing requires individualized monitoring.
What role Isman played (founder, advisor, investigator) is not clear from public data.
Beyond rapamycin, Isman is also linked to NAD (nicotinamide adenine dinucleotide) metabolism. Rapamycin appears in other platform contexts: Peter Fedichev, the OpenDrugs project, and the ERAP protocol (Phase IIa, rapamycin in Alzheimer's disease and aging, in vivo imaging).
High-confidence person-term association with a named concrete mechanism: AgelessRx paired prescription access with rapamycin-trial participation, making this a clear example of how off-label longevity pharmacology generates structured trial data from a paying customer base rather than from traditional recruitment.